- Home
- NVA vs ADAP Comparison
NVA vs ADAP Comparison
Compare NVA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- ADAP
- Stock Information
- Founded
- NVA 1987
- ADAP 2008
- Country
- NVA Australia
- ADAP United Kingdom
- Employees
- NVA N/A
- ADAP N/A
- Industry
- NVA
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- ADAP Health Care
- Exchange
- NVA NYSE
- ADAP Nasdaq
- Market Cap
- NVA 65.4M
- ADAP 75.5M
- IPO Year
- NVA N/A
- ADAP 2015
- Fundamental
- Price
- NVA $9.46
- ADAP $0.28
- Analyst Decision
- NVA
- ADAP Buy
- Analyst Count
- NVA 0
- ADAP 6
- Target Price
- NVA N/A
- ADAP $1.35
- AVG Volume (30 Days)
- NVA 50.4K
- ADAP 541.0K
- Earning Date
- NVA 01-01-0001
- ADAP 08-11-2025
- Dividend Yield
- NVA N/A
- ADAP N/A
- EPS Growth
- NVA N/A
- ADAP N/A
- EPS
- NVA N/A
- ADAP N/A
- Revenue
- NVA N/A
- ADAP $179,639,000.00
- Revenue This Year
- NVA N/A
- ADAP N/A
- Revenue Next Year
- NVA N/A
- ADAP $37.22
- P/E Ratio
- NVA N/A
- ADAP N/A
- Revenue Growth
- NVA N/A
- ADAP 878.53
- 52 Week Low
- NVA $4.35
- ADAP $0.20
- 52 Week High
- NVA $19.00
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- ADAP 54.14
- Support Level
- NVA N/A
- ADAP $0.27
- Resistance Level
- NVA N/A
- ADAP $0.29
- Average True Range (ATR)
- NVA 0.00
- ADAP 0.02
- MACD
- NVA 0.00
- ADAP 0.00
- Stochastic Oscillator
- NVA 0.00
- ADAP 74.29
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.